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ABSTRACT
Background: The purpose of this study was to test whether immunohistochemical 
(IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict 
similar numbers of patients with favorable prognoses as genomic markers. 
Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 
levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-
Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate 
signature(GSS) (66.7%: 20/30), but the difference in predictive power was not 
significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) 
and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly 
downregulated after therapy (P < 0.001 and 0.041, respectively).
Materials and Methods: Core needle biopsy specimens of primary breast cancer 
were collected at Okayama University Hospital from hormone receptor-positive and 
human epidermal growth factor 2-negative patients that subsequently received two 
weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from 
surgical samples were also collected. IHC Ki67 levels and GSS were compared between 
pre- and post-hormone treatment samples. Changes of gene expression pattern in 
short-term hormone therapy were also assessed. 
Conclusions: IHC based post-Ki67 levels may have distinct predictive power 
compared with the naïve IHC Ki67. Future studies with larger cohorts and longer 
follow-up periods may be needed to validate our results.
INTRODUCTION
Genomic signatures can predict prognoses of 
cancer patients to indicate which patients do not need 
chemotherapy and which are most likely to respond 
to chemotherapy. These signatures are more precise 
than classical clinicopathological biomarkers, such as 
histological grade and immunohistochemical (IHC) 
assessment of Ki67 among patients with hormone 
receptor (HR) positive (+)/human epidermal growth 
factor receptor 2 (HER2) negative (−) breast cancer [1]. 
The National Comprehensive Cancer Network (NCCN) 
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guidelines recommend using a validated 21-gene reverse 
transcription polymerase chain reaction (RT-PCR) 
prognostic assay to guide treatment management when 
combining chemotherapy with standard hormone therapy 
[2]. Reducing unnecessary chemotherapy for HR+/HER2− 
breast cancer cases is one of the greatest advantages of 
using genomic signatures to design treatment practices 
[3]. However, the high cost of genomic signature testing 
(e.g. the Oncotype DX® test costs currently $4,175) limits 
clinical access to this diagnostic technology in many 
countries outside of the US and Western Europe. 
Dowsett et al recently showed that an inexpensive 
biomarker assay using IHC Ki67 after short-term 
preoperative hormone therapy had improved predictive 
power for breast cancer prognosis [4]. IHC Ki67 levels 
after short-term hormone therapy were significantly lower 
than naïve IHC Ki67 levels [5]. However, it is unknown 
if IHC Ki67 after short-term hormone therapy (post-
Ki67) can predict favorable prognoses among HR+ breast 
cancer cases as accurately as genomic signatures can. No 
clinical studies have examined both genomic signatures 
and post-Ki67 levels to allow the predictive functions of 
the distinct markers to be directly assessed on the same 
cohort of patients.
The purpose of this study was to compare the 
predictive power of post-Ki67 to known genomic 
markers and to assess changes of gene expression pattern 
associated with short-term hormone therapy. 
RESULTS
Thirty paired cases (60 samples) with HR+/
HER2− breast cancer were enrolled in this study. Patient 
characteristics are shown in Table 1. Of these, 14 cases 
(46.7%) were clinical T1 breast cancers and no patients 
had clinical lymph node metastasis. All cases were HR+ 
and HER2−, and 25 cases (83.3%) were PgR+. Over half 
of the cases (53.3%) were histological grade I. Eleven 
cases (36.7%) received tamoxifen and the remaining 19 
cases received letrozole as the preoperative short-term 
hormone therapy. 
IHC Ki67 and genomic surrogate signature 
(GSS) after short-term hormone therapy
Seventeen cases (56.6%) were assigned to the low-
risk group according to pre-treatment Ki67 (pre-Ki67) 
levels and 25 cases (83.3%) were assigned to the low-
risk group according to post-Ki67 levels (Figure 1). The 
average pre- and post-Ki67 levels were 15.9% and 7.6%, 
respectively. Pre-Ki67 levels were significantly higher 
than post-Ki67 (P < 0.001) (Figure 2A). Pre-treatment 
GSS stratified 20 cases (66.7%) into the low-risk group. 
Twenty-four cases (80%) were classified as low-risk by 
post-treatment GSS. Pre- and post-therapy recurrence 
scores according to GSS were not significantly different 
(P = 0.366) (Figure 2B). Post-Ki67 predicted more low-
risk cases (83.3%, 25/30) than pre-GSS (66.7%: 20/30), 
but the difference in predictive power was not significant 
(P = 0.233). All cases assigned to the low-risk group 
by pre-Ki67 (n = 17) and pre-GSS (n = 20) were again 
stratified into low-risk group by post-treatment Ki67 and 
GSS. Conversely, more than half of cases assigned to 
the high-risk group by pre-Ki67 (8/13) and 40% (4/10) 
of cases assigned to the intermediate- or high-risk groups 
by pre-GSS were reclassified into low-risk group by post-
treatment markers.      
Changes of gene expression pattern associated 
with short-term hormone therapy
We compared gene expression levels of four clinically 
important genes before and after hormone therapy. After 
short-term hormone therapy, PGR (208305_at) and MKI67 
(212020_s_at) were significantly downregulated (P = 0.043 
and P < 0.001, respectively), and ESR1 (205225_at) levels 
were marginally lower (P = 0.055) (Supplementary Figure 1). 
ERBB2 (216836_s_at) levels were unaffected by the 
hormone treatment (P = 0.458). 
Next, we assessed four biological functions and three 
independent genes from the 21-gene assay before and after 
therapy. Proliferation (MKI67, STK15, Survivin, CCNB1, 
and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) 
were significantly downregulated after short-term hormone 
therapy (P < 0.001 and 0.041, respectively) (Figure 3). 
Two biological functions (invasion and HER2) and three 
independent genes (GSTM1, CD68, and BAG1) were 
unaffected by the treatment (Supplementary Figure 2).  
DISCUSSION
Short-term hormone therapy is easily accessible, 
affordable, and has minimal side effects. Indeed, all patients 
in this study completed two weeks of hormone therapy 
without any side effects. Our study has notable findings 
regarding the impact of preoperative short-term hormone 
therapy for patients with HR+/HER2− breast cancers. 
First, post-Ki67 levels classified as many low-risk 
cases as genomic markers. This finding suggests that 
post-Ki67 can be used as a reliable substitute for genomic 
testing. While genomic testing is likely to improve 
survival and quality-adjusted life expectancy in patients 
with high recurrence risks [6, 7], the cost of genomic 
testing limits its use outside the US and parts of Europe. 
Thus, identifying a low-cost marker such as IHC Ki67 
that is as reliable as traditional genomic testing is critical 
to improve global cancer treatment strategies. Because 
no risk assessment method provides perfect predictions, 
additional biomarkers for HR+/HER2− breast cancers 
can help determine when patients classified as high-risk 
do not need chemotherapy or when patients classified as 
low-risk do require chemotherapy. In this study, short-
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term preoperative hormone therapy stratified all low-risk 
patients into the low-risk group according to pre-treatment 
biomarker levels. However, some patients designated as 
high-risk by pre-treatment biomarkers were classified to 
the low-risk group by post-treatment biomarkers. This 
finding suggests that our strategy might be more useful 
in determining when high-risk patients do not require 
chemotherapy than in revealing low-risk patients who do 
need chemotherapy. In this study we merged intermediate 
with the high risk group in the GSS. From the previous 
paper for the prospective study “TAILORx”, cases with 
a recurrence score of 0 to 10 with endocrine therapy 
alone without chemotherapy should have a very low 
risk of recurrence, indicating they do not need adjuvant 
chemotherapy [8], although we have no prospective data 
to skip chemotherapy for cases with intermediate risk at 
present. We need the additional evidence whether cases 
with intermediate risk can skip chemotherapy or not. This 
coming evidence may effect on our results.       
Second, preoperative hormone therapy for only two 
weeks stimulated dynamic changes in gene expression 
pattern. We observed proliferation and estrogen associated 
genes were significantly downregulated after short-term 
hormone therapy. Consistent with our findings, Dowsett et 
al report that proliferation-associated genes and classical 
estrogen-dependent genes were strongly downregulated, 
and that higher expression of immune-related genes 
was associated with poorer responses [9]. Miller et al 
Table 1 Patient characteristics*
Age Average (min.-max) 59.5 (40–88)
Number of samples %
cTumor size
T1 14 46.7%
T2 15 50.0%
T3 1 3.3%
T4 0 0.0%
cN
Positive 0 0.0%
Negative 30 100.0%
ER
Positive 30 100.0%
Negative 0 0.0%
PgR
Positive 25 83.3%
Negative 5 16.7%
HER2
Positive 0 0.0%
Negative 30 100.0%
Historogical grade
I 16 53.3%
II 11 36.7%
III 2 6.7%
Unknown 1 3.3%
Hormone therapy
Tamoxifen 11 36.7%
Letrozole 19 63.3%
Operation
Total mastectomy 12 40.0%
Partial mastectomy 18 60.0%
Abbreviations: *c: Clinical; ER: Estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor 
receptor 2.
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also found dynamic patterns of differential expression 
of proliferation and ER genes  [10]. Two weeks of 
preoperative hormone therapy is trivial compared to the 
traditional five years of postoperative hormone treatment. 
However, there may be biological differences between 
adjuvant therapies that target unknown cancer stem cells 
and neoadjuvant therapies that target existing tumors. The 
results of the ongoing POETIC trials to determine whether 
Figure 1: Differences in risk categories by pre- and post-treatment markers.
Figure 2: IHC Ki67 levels and web-based risk scores before and after short-term hormone therapy. (A) The IHC Ki67 
level was defined as the percentage of Ki67-positive cells. The dotted line shows the cutoff IHC Ki67 level at 13.25%. (B) The web-based 
risk score was simulated [17]. The dotted line shows the cutoff for low and intermediate risk groups. P values were calculated by the 
Wilcoxon test.
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preoperative endocrine therapy improves breast cancer 
treatment outcomes are eagerly awaited [11]. 
Interestingly, the genomic changes observed after 
hormone therapy do not align perfectly with a previous 
study [12]. This disagreement may have arisen because the 
first-generation genomic marker that was found to be highly 
associated with proliferation was composed of several 
functions and genes, and the previous study calculated 
risk scores as coefficients of those genes. We found 
that both proliferation and estrogen were significantly 
decreased after hormone treatments. While proliferation 
was positively correlated with the recurrence score, 
estrogen was negatively correlated with recurrence score 
[12]. In light of these conflicting findings, recurrence 
scores calculated by GSS might be relatively unaffected by 
short-term hormone therapy. These results are consistent 
with the previous paper [13]. The study by Ueno et al. 
compared the 21-gene assay Recurrence Score®(RS) 
between pre and post 6 months-hormone therapy and 
demonstrated no statistically significant difference in the 
hormone therapy (P = 0.484) [13]. 
A strength of this study is that both IHC Ki67 levels 
and genomic profiling data were available on paired 
samples. Therefore, the predictive power of IHC Ki67 
and the genomic marker could be directly compared. 
However, this study has several limitations. The sample 
size of this study is small, and thus, our findings must 
be interpreted cautiously. Variability in IHC Ki67 counts 
between technical replicates and different pathologists 
were assessed, as reproducibility and consistency of IHC 
Ki67 testing are always debated [14, 15]. Heterogeneous 
treatments (tamoxifen or letrozole) may also affect the 
results. Furthermore, the tumor samples collected by core 
needle biopsy at diagnosis and during surgery could vary 
because of heterogeneity within the tumor. Different tissue 
samples from the same tumor may have different IHC levels 
and distinct gene expression profiles. Nevertheless, we 
believe that our findings are generalizable and are consistent 
with Ki67 levels and biological changes after short-term 
hormone therapy observed in other studies [4, 9]. 
In conclusion, our study assessed the effect of 
preoperative short-term hormone therapy on treatment 
outcomes and found that IHC based post-Ki67 levels 
may have distinct predictive power compared with the 
naïve IHC Ki67. Future studies with larger cohorts and 
longer follow-up periods may be needed to further test 
the efficacy of IHC Ki67 after short-term preoperative 
hormone therapy.
MATERIALS AND METHODS
Patient cohort and gene expression data
Core needle biopsy (Cx) with 14G or 16G for 
primary cancer specimens were collected at Okayama 
University Hospital from HR+/HER2− patients that 
subsequently received two weeks of neoadjuvant hormone 
therapy. Thirty clinical TNM stage I and II women 
were enrolled in this study. The study was approved by 
the Institutional Review Board and all patients signed 
informed consent forms. Patients received preoperative 
hormone therapy daily for two weeks before surgery. 
Premenopausal patients received tamoxifen (20 mg) and 
postmenopausal patients received letrozole (2.5 mg). All 
patients underwent a mastectomy or breast-conserving 
surgery. Surgical samples after treatment were also 
collected. Hormone and HER2 receptor statuses were 
determined in the diagnostic Cx specimens before 
Figure 3: Gene expression before and after short-term hormone therapy. (A) Proliferation-associated (MKI67, STK15, 
Survivin, CCNB1, and MYBL2) and (B) estrogen-associated (ER, PGR, BCL2, and SCUBE2) genes refer to average expression values [12]. 
P values were calculated by the Wilcoxon test.
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hormone therapy. Cases with ≥1% positive nuclear 
staining for estrogen receptors (ER) or progesterone 
receptors (PgR) with IHC were considered hormone 
receptor-positive. Cases with either 0 or 1 positive IHC 
staining for HER2 or with a HER2 gene copy number 
< 2.0 by fluorescent in situ hybridization (FISH) 
analysis were considered HER2−. IHC staining for Ki67 
established a proliferation index and was assessed pre- 
and post-neoadjuvant hormone therapy. The IHC Ki67 
assay was performed using the MIB-1 antibody (Dako; 
Glostrup, Denmark) on the immunostainer system (Dako). 
Photomicrographs were taken under 40× magnification 
and the percentage of Ki67-positive cells was scored. 
Where possible, 1,000 malignant cells (at least 500 cells) 
were viewed. Replicate counts by two trained physicians 
were averaged to calculate % Ki67-positive cells. HR+/
HER2− cases were divided into low and high Ki67 
groups using the 13.25% Ki67 cutoff point as previously 
described by Cheang et al. [16].
 Matching pre and post hormone therapy frozen 
specimens for gene expression analysis were collected 
into RNA and later stored at –80°C. RNA from breast 
specimens was isolated, and quantity and quality of 
the each RNA was using an Agilent 2100 Bioanalyzer 
(Agilent Technologies). Genome-wide expression levels 
of transcripts were analyzed using the Affymetrix U133A 
gene chips (Affymetrix) according to the manufacture’s 
instructions. Complete gene expression data are available 
in the Gene Expression Omnibus (GEO) under accession 
number GSE80077. 
Bioinformatics and statistical analysis  
We developed a genomic surrogate signature 
(GSS) simulated from Recurrence Online (http://www.
recurrenceonline.com/) to calculate the recurrence score 
(0–100) and recurrence risk (low, intermediate, and high) 
using predefined sets of genes that were quantified by a 
cDNA microarray [17]. Breast cancers were stratified as 
low (score 0–17), intermediate (score 18–30), or high 
(score 31–100) risk using the GSS. First, we assessed how 
many patients were stratified to two groups (high or low 
risk group) by pre- or post-treatment GSS and IHC Ki67. 
We compared the recurrence score and IHC Ki67 levels 
before and after hormone therapy using a Wilcoxon test. 
Next, we compared pre- and post-hormone therapy 
expression levels of four genes (ER, PgR, HER2, and 
Ki67) that are used clinically to inform breast cancer 
treatment strategies. Next, we measured expression 
changes of genes involved in key biological markers 
and functions using the 21-gene assay to investigate the 
effect of short-term hormone therapy on these genomic 
markers. The 21-gene assay was composed genes involved 
in four biological functions (Proliferation: MKI67, STK15, 
Survivin, CCNB1, and MYBL2; Invasion: MMP11 and 
CTSL2; HER2: GRB7 and HER2; Estrogen: ER, PGR, 
BCL2, and SCUBE2), three independent genes (GSTM1, 
CD68, and BAG1) and five reference genes [12]. We 
compared the average pre- and post-hormone therapy gene 
expression levels of each biological function and of the 
four genes. 
All statistical analyses were performed using BRB-
ArrayTools version 3.9.0a (http://linus.nci.nih.gov/BRB-
ArrayTools.html) and R software version 2.7.2 (http://
www.r-project.org). Two-sided P values ≤ 0.05 were 
considered statistically significant.
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